{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:58:00Z","timestamp":1781830680536,"version":"3.54.5"},"reference-count":63,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>In patients with diffuse large B-cell lymphoma (DLBCL), concurrent deregulation of MYC and BCL2 confers inferior outcomes following R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). DA\u2013EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) produces favorable results in patients with dual MYC and BCL2 rearrangement (double-hit lymphoma [DHL]), but there are limited prospective data in both DHL and DLBCL with dual protein overexpression of Myc and Bcl2 (double-expressor lymphoma [DEL]). Lenalidomide (LEN) may enhance the response in MYC-driven lymphomas, prompting this investigator-initiated multicenter phase 1\/2 study evaluating LEN with DA\u2013EPOCH-R in adults with newly diagnosed DHL and DEL. Fifty-five patients (DHL, 23; DEL, 32) were enrolled and treated. Patients had a median age of 65 years (range, 25-82), International Prognostic Index \u22653 in 69% (38\/55), and stage III\/IV in 91% (50\/55). The overall response rate was 90.9%, with a complete response rate of 83.6%. With a median follow-up of 3.4 years, the primary end point efficacy criterion was met with 1- and 2-year progression-free survival (PFS) rates of 85.5% and 78.2%, respectively. The 2-year overall survival was 83.6%. The most common adverse events (grade \u22653) were neutropenia (67%), anemia (67%), thrombocytopenia (49%), and neutropenic fever (35%). There were no grade 5 events. Second primary malignancy occurred in 6 patients (11%). LEN with DA\u2013EPOCH-R for patients with DEL and DHL has a high response rate, encouraging survival, and met the primary PFS efficacy criterion. A randomized trial of DA\u2013EPOCH-R with and without LEN would be needed to determine the specific benefit of LEN. This trial was registered at www.ClinicalTrials.gov as #NCT02213913.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017092","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T20:08:37Z","timestamp":1753733317000},"page":"5665-5675","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["A multicenter phase 1\/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL"],"prefix":"10.1182","volume":"9","author":[{"given":"Kirk","family":"Cahill","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Medicine, Loyola University Medical Center, Maywood, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4103-4288","authenticated-orcid":false,"given":"James","family":"Godfrey","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Nabhan","sequence":"additional","affiliation":[{"name":"3Ryght, Inc, Anaheim, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kline","sequence":"additional","affiliation":[{"name":"4Section of Hematology\/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Riedell","sequence":"additional","affiliation":[{"name":"4Section of Hematology\/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth S.","family":"Cohen","sequence":"additional","affiliation":[{"name":"4Section of Hematology\/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Narula","sequence":"additional","affiliation":[{"name":"4Section of Hematology\/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore G.","family":"Karrison","sequence":"additional","affiliation":[{"name":"5Department of Public Health Sciences, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Robertson","sequence":"additional","affiliation":[{"name":"4Section of Hematology\/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-4376","authenticated-orcid":false,"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Venugopal","sequence":"additional","affiliation":[{"name":"7Division of Hematology\/Oncology, Rush University Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1835-2998","authenticated-orcid":false,"given":"Seo-Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"7Division of Hematology\/Oncology, Rush University Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0043-3562","authenticated-orcid":false,"given":"Aaron P.","family":"Rapoport","sequence":"additional","affiliation":[{"name":"8Division of Hematology\/Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Tae","family":"Lee","sequence":"additional","affiliation":[{"name":"8Division of Hematology\/Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Law","sequence":"additional","affiliation":[{"name":"8Division of Hematology\/Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A. S.","family":"Fishkin","sequence":"additional","affiliation":[{"name":"9Illinois CancerCare, Peoria, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Isufi","sequence":"additional","affiliation":[{"name":"10Hematology, Department of Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Velasco","sequence":"additional","affiliation":[{"name":"11Cancer Care Center of Decatur, Decatur, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Kaminer","sequence":"additional","affiliation":[{"name":"12Northshore University Health System, Evanston, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9893-4949","authenticated-orcid":false,"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[{"name":"4Section of Hematology\/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"15","key":"2025111111211168200_bib1","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"35","key":"2025111111211168200_bib2","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.19.00743","article-title":"Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium","volume":"37","author":"Rosenwald","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025111111211168200_bib3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2025111111211168200_bib4","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"20","key":"2025111111211168200_bib5","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"28","key":"2025111111211168200_bib6","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"20","key":"2025111111211168200_bib7","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1200\/JCO.2017.72.2157","article-title":"Outcomes of patients with double-hit lymphoma who achieve first complete remission","volume":"35","author":"Landsburg","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025111111211168200_bib8","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol"},{"issue":"21","key":"2025111111211168200_bib9","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15","key":"2025111111211168200_bib10","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","article-title":"A phase 2\/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator\u2019s choice in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"23","author":"Czuczman","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2025111111211168200_bib11","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype","volume":"117","author":"Hernandez-Ilizaliturri","year":"2011","journal-title":"Cancer"},{"issue":"12","key":"2025111111211168200_bib12","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/leu.2011.165","article-title":"Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study","volume":"25","author":"Nowakowski","year":"2011","journal-title":"Leukemia"},{"issue":"3","key":"2025111111211168200_bib13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025111111211168200_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response","volume":"154","author":"Lopez-Girona","year":"2011","journal-title":"Br J Haematol"},{"issue":"6","key":"2025111111211168200_bib15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"issue":"14","key":"2025111111211168200_bib16","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/onc.2015.245","article-title":"Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors","volume":"35","author":"Gopalakrishnan","year":"2016","journal-title":"Oncogene"},{"issue":"16","key":"2025111111211168200_bib17","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2014-11-567792","article-title":"Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities","volume":"125","author":"Kritharis","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2025111111211168200_bib18","first-page":"7967","article-title":"NF-kappa B sites function as positive regulators of expression of the translocated c-myc allele in Burkitt\u2019s lymphoma","volume":"14","author":"Ji","year":"1994","journal-title":"Mol Cell Biol"},{"issue":"11","key":"2025111111211168200_bib19","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/cncr.31877","article-title":"Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2","volume":"125","author":"Godfrey","year":"2019","journal-title":"Cancer"},{"issue":"20","key":"2025111111211168200_bib20","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2025111111211168200_bib21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2025111111211168200_bib22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025111111211168200_bib23","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood.V99.8.2685","article-title":"Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy","volume":"99","author":"Wilson","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2025111111211168200_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/10428194.2022.2140281","article-title":"A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double\/triple-hit lymphoma","volume":"64","author":"Cortese","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2025111111211168200_bib25","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1182\/blood-2023-181707","article-title":"DA-EPOCH-R for high grade B-cell lymphoma patients with MYC and BCL2 and\/or BCL6 rearrangements: clinical results of the induction phase of the HOVON-152 trial","volume":"142","author":"de Jonge","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2025111111211168200_bib26","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3324\/haematol.2021.278638","article-title":"Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome","volume":"107","author":"Dodero","year":"2022","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2025111111211168200_bib27","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2021-145954","article-title":"Population-wide introduction of dose-adjusted EPOCH-R is associated with improved outcome of high grade B-cell lymphoma with MYC and BCL2 rearrangements with diffuse large B-cell lymphoma morphology","volume":"138","author":"Alduaij","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2025111111211168200_bib28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41408-023-00827-5","article-title":"A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications","volume":"13","author":"El-Sharkawi","year":"2023","journal-title":"Blood Cancer J"},{"issue":"20","key":"2025111111211168200_bib29","first-page":"2493","article-title":"Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population","volume":"141","author":"Alduaij","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2025111111211168200_bib30","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3324\/haematol.2022.281461","article-title":"Modern, real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large B-cell lymphoma with or without double\/triple-hit status in the United States","volume":"108","author":"Goyal","year":"2023","journal-title":"Haematologica"},{"issue":"12","key":"2025111111211168200_bib31","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.3324\/haematol.2019.238162","article-title":"Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial","volume":"105","author":"Chamuleau","year":"2020","journal-title":"Haematologica"},{"issue":"26","key":"2025111111211168200_bib32","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","article-title":"Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies","volume":"33","author":"Scott","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025111111211168200_bib33","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.20.01366","article-title":"ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025111111211168200_bib34","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1200\/JCO.22.00597","article-title":"Smart start: rituximab, lenalidomide, and ibrutinib in patients with newly diagnosed large B-cell lymphoma","volume":"41","author":"Westin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025111111211168200_bib35","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/bloodadvances.2022008174","article-title":"A phase 1\/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL","volume":"7","author":"Cherng","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2025111111211168200_bib36","doi-asserted-by":"crossref","first-page":"e947","DOI":"10.1016\/j.clml.2022.06.013","article-title":"R-CHOP vs DA-EPOCH-R for double-expressor lymphoma: a University of California hematologic malignancies consortium retrospective analysis","volume":"22","author":"Othman","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2025111111211168200_bib37","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/bloodadvances.2023011369","article-title":"A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen","volume":"8","author":"Karmali","year":"2024","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025111111211168200_bib38","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood-2021-151266","article-title":"Randomized phase II\/III study of DA-EPOCH-R +\/- venetoclax in previously untreated double hit lymphoma: initial results from alliance A051701","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood"},{"issue":"16_suppl","key":"2025111111211168200_bib39","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.1200\/JCO.2024.42.16_suppl.7012","article-title":"Randomized phase II\/III study of R-CHOP +\/- venetoclax in previously untreated MYC\/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701","volume":"42","author":"Abramson","year":"2024","journal-title":"J Clin Oncol"},{"issue":"17_suppl","key":"2025111111211168200_bib40","doi-asserted-by":"crossref","first-page":"LBA7003","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA7003","article-title":"Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: an interim analysis from the phase III DEB study","volume":"42","author":"Zhao","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025111111211168200_bib41","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.clml.2018.08.014","article-title":"Complications associated with dose-adjusted EPOCH-rituximab therapy for non-Hodgkin lymphoma","volume":"18","author":"David","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2025111111211168200_bib42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"2025111111211168200_bib43","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.20.01375","article-title":"Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025111111211168200_bib44","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/bloodadvances.2022009145","article-title":"Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas","volume":"7","author":"Lynch","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"2025111111211168200_bib45","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-018-0145-9","article-title":"Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials","volume":"8","author":"Castellino","year":"2018","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2025111111211168200_bib46","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood-2024-197938","article-title":"Five-year analysis of the POLARIX study: prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes","volume":"144","author":"Salles","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025111111211168200_bib47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-020-00900-7","article-title":"A randomized, open-label, phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma: final analysis of GOYA","volume":"13","author":"Sehn","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2025111111211168200_bib48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/cncr.32513","article-title":"Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis","volume":"126","author":"Major","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"2025111111211168200_bib49","doi-asserted-by":"crossref","first-page":"101035","DOI":"10.1016\/j.adro.2022.101035","article-title":"Second primary malignancies in diffuse large B-cell lymphoma survivors with 40 years of follow up: influence of chemotherapy and radiation therapy","volume":"7","author":"Rock","year":"2022","journal-title":"Adv Radiat Oncol"},{"issue":"12","key":"2025111111211168200_bib50","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"16","key":"2025111111211168200_bib51","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2025111111211168200_bib52","doi-asserted-by":"crossref","first-page":"e906","DOI":"10.1016\/S2352-3026(22)00289-7","article-title":"Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Saleem","year":"2022","journal-title":"Lancet Haematol"},{"issue":"suppl 16","key":"2025111111211168200_bib53","doi-asserted-by":"crossref","first-page":"7517","DOI":"10.1200\/JCO.2022.40.16_suppl.7517","article-title":"Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX trial","volume":"40","author":"Morschhauser","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025111111211168200_bib54","unstructured":"United State Food and Drug Administration\n          . FDA approves polatuzumab vedotin-piiq for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma. Accessed 29 April 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-polatuzumab-vedotin-piiq-previously-untreated-diffuse-large-b-cell-lymphoma-not."},{"issue":"suppl 1","key":"2025111111211168200_bib55","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2024-203135","article-title":"Golcadomide (GOLCA) plus R-CHOP has high minimal residual disease (MRD) negativity across high-risk, untreated aggressive B-cell lymphoma (a-BCL)","volume":"144","author":"Amzallag","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2025111111211168200_bib56","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2025111111211168200_bib57","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood-2023-174510","article-title":"3-year analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL)","volume":"142","author":"Chavez","year":"2023","journal-title":"Blood"},{"issue":"suppl 16","key":"2025111111211168200_bib58","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1200\/JCO.2023.41.16_suppl.7519","article-title":"Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit\/triple-hit lymphoma: updated EPCORE NHL-2 data","volume":"41","author":"Falchi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"2025111111211168200_bib59","doi-asserted-by":"crossref","first-page":"7549","DOI":"10.1200\/JCO.2023.41.16_suppl.7549","article-title":"Glofitamab + pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): results from a phase Ib study","volume":"41","author":"Dickinson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"2025111111211168200_bib60","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","article-title":"Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials","volume":"36","author":"Maurer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"16","key":"2025111111211168200_bib61","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1182\/bloodadvances.2024012838","article-title":"Evaluating the impact of laboratory-based eligibility criteria by race\/ethnicity in first-line clinical trials of DLBCL","volume":"8","author":"Khurana","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"2025111111211168200_bib62","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025111111211168200_bib63","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.18.01314","article-title":"Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy","volume":"37","author":"Sha","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5665\/2419768\/blooda_adv-2025-017092-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5665\/2419768\/blooda_adv-2025-017092-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:21:23Z","timestamp":1762878083000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/21\/5665\/546387\/A-multicenter-phase-1-2-trial-of-lenalidomide-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":63,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017092","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,11]]},"published":{"date-parts":[[2025,11,11]]}}}